

# KRATOM FACT SHEET

## LET SCIENCE DIRECT PUBLIC POLICY ON KRATOM – NOT THE FDA BIAS AGAINST ALL DIETARY AND BOTANICAL SUPPLEMENTS

### *Dispelling Myths and Understanding the Facts*

More than 15 million Americans safely use kratom as a part of their health and well-being regimen and have done so for decades. Kratom is regulated by the U.S. Food and Drug Administration (FDA) as a dietary ingredient/supplement, and people who use kratom do so for the same reasons as people who use dietary ingredients, supplements, and who drink coffee, tea, or other caffeinated beverages. Surveys show that kratom consumers are educated, middle-income, employed, and have health insurance – they are largely the soccer moms and dads of America.

The FDA has repeatedly attempted to force kratom into Schedule I of the Controlled Substances Act by misstating the science, ignoring kratom’s long history of safe use, and falsely claiming kratom has the same effects as classic opioids. The FDA’s distorted record on kratom is clearly a part of the FDA’s long-standing bias against dietary supplements that are safely used by millions of Americans rather than chemical drug formulations that are subject to new drug applications that have their own potential and frequently serious adverse health impacts.

Dispelling the FDA Myths	Understanding the Facts
<p><b>The FDA claims there are deaths associated with kratom use and warns consumers from using it.</b></p>	<p>There has not been a single documented fatality that can be linked to use of the natural kratom plant alone. The FDA claimed deaths “associated with kratom use” are actually deaths caused by polydrug use, underlying medical conditions, or the use of adulterated kratom products laced with toxic levels of dangerous substances, including opioids. National Institutes on Drug Abuse’s (NIDA) newly-updated conclusions agree that unadulterated kratom use does not cause overdose deaths.</p>
<p><b>Kratom’s primary alkaloid, mitragynine (MG) and metabolite 7-hydroxymitragynine (7-HMG) are dangerous opioids and have the same effects of opioids like heroin.</b></p>	<p>MG and 7-HMG, like many other substances like Chamomile, St. John’s Wort, etc., do bind to the mu-opioid receptors in the brain. Kratom’s alkaloids are actually only partial agonists, with lower dependence and abuse potential. The sectors of the brain kratom impacts are pain relief and mood sectors, not the sector that produced euphoria and, most importantly, scientific evidence demonstrates that kratom does not cause respiratory depression like classic opioids, a common cause of fatal overdoses.</p>
<p><b>Kratom is highly addictive and is abused as a drug</b></p>	<p>Like coffee, tea, and other caffeinated drinks, consumers can develop a dependency on kratom, which is vastly different from an addiction. Two NIDA funded scientific studies completely debunk the FDA theory. The Hemby study in June 2018 concluded “MG does not have abuse potential and reduces morphine intake,” and the Yue study in July 2018 reported “limited abuse liability and potential for mitragynine treatment to specifically reduce opioid abuse.” Recent studies confirm that fact.</p>
<p><b>The kratom industry has no production standards or consumer safety protocols.</b></p>	<p>The American Kratom Association (AKA) is committed to supporting regulations that provide consumers with safe, properly manufactured kratom products. The kratom community supports adherence to FDA product testing protocols that meet or exceed Good Manufacturing Practice (GMP) guidelines set by the FDA for dietary ingredients/supplements and support appropriate age restrictions and labeling guidelines outlining responsible use. The kratom community has called upon the FDA to use its existing regulatory authority to remove adulterated kratom products from the market and prosecute individuals or companies who produce or distribute dangerous adulterated kratom products, but in more than 65 reports provided by the AKA, not a single prosecution by the FDA.</p>

The kratom community believes public policy related to kratom should follow the science. To learn more about the science that supports the fact that kratom is a safe natural botanical, and why the FDA claims being made about kratom are just wrong, visit the following page to download and review the compelling truth about kratom use by consumers: [www.kratomanswers.org](http://www.kratomanswers.org)

# KEY KRATOM QUESTIONS AND ANSWERS

---

## Why does the FDA claim kratom is unsafe for consumers?

The FDA has a long-standing bias against any dietary ingredient, botanical supplement, or dietary supplement that is not a chemical formulation subject to regulatory approval as a new drug. In 1994, Congress passed the Dietary Supplement Health and Education Act (DHEA) to reign in the FDA's overregulation of dietary supplements FDA wanted banned on the premise they were highly addictive, being used to self-medicate without physician supervision, or were so poorly formulated these products posed a threat to public health requiring them to be banned.

Today, FDA maintains the same three common objections about kratom, i.e., kratom is unsafe, is highly addictive, and has no approved medical use — and people are using it to self-medicate to withdraw from opioid addictions. Accordingly, FDA has made three specific attempts to have kratom's constituents, mitragynine and 7-hydroxymitragynine, as Schedule I substances. Based on current science, leading public health officials have reviewed the current evidence and data on kratom and vigorously disagree with the FDA's assessment of kratom's addiction and safety profile. All three of the FDA's recommendations for scheduling have been rejected by the Drug Enforcement Administration; the U.S. Department of Health and Human Services (HHS); and the Expert Committee on Drug Dependence (ECDD) for the U.N. Commission on Narcotic Drugs.

## The FDA claims kratom should be classified as a Schedule I substance, so why is kratom not scheduled today at the federal level?

The short answer is because the FDA is wrong on the science, and wrong on the policy. Other federal and international agencies have carefully evaluated the FDA's claims and they find they lack sufficient evidence to support the FDA claims.

- October 13, 2016: The DEA withdrew the Notice of Intent recommending the temporary scheduling of kratom and requested a full 8-Factor Analysis from the FDA.
- August 16, 2018: HHS Assistant Secretary for Health, Brett Giroir, M.D., formally withdrew the FDA scheduling recommendation for kratom that had been submitted to the DEA and called out the FDA for "disappointingly poor evidence & data and a failure to consider the overall public health."
- December 1, 2021: The Expert Committee on Drug Dependence at the World Health Organization and the U.S. Commission of Narcotic Drugs, comprised of 12 international experts on substance safety and addiction, unanimously concluded that there was insufficient evidence to recommend a critical international scheduling review of kratom.

- March 16, 2022: Letter from HHS Secretary Becerra acknowledging “knowledge gaps” on kratom and that “kratom-involved overdose deaths have occurred after use of adulterated kratom products or taking kratom with other substances.”
- December 29, 2022: President Biden signs the FY23 Omnibus with kratom report language commending NIDA for funding studies on kratom that “may provide help for some Americans struggling with addictions, given its analgesic and less addictive properties as compared to opioids.”

### **Is it true there is no approved medical use for kratom?**

That claim is true, but it is also true for tens of thousands of foods, dietary ingredients, botanical supplements, and dietary supplements that are available to consumers in the U.S., many of which are regularly used to self-medicate by consumers to maintain their health and well-being. Federal law provides adequate authority for the FDA to prosecute any vendors who make illegal therapeutic claims to induce consumers to buy their products for therapeutic uses. In response, the AKA has submitted 65 documented cases of kratom vendors using illegal marketing claims on some therapeutic benefits they claim are associated with kratom consumption. Despite having sufficient legal authority to protect consumers from such illegal marketing schemes, the FDA has not initiated a single prosecution against any of those violators.

### **How many states have enacted the Kratom Consumer Protection Act?**

As of today, 9 states have passed similar versions of the KCPA: Utah, Georgia, Arizona, Nevada, Oregon, Colorado, Oklahoma, West Virginia, and Virginia.

The Texas Senate passed the KCPA on a vote of 28-2 on March 16 and is now being considered by the Texas House. Additional states currently deliberating on KCPAs are Kansas, Illinois, Indiana, Michigan, Minnesota, Tennessee, Ohio, Pennsylvania, New Jersey, New York, Florida, North Carolina, Arkansas, Louisiana, South Carolina, Vermont, Wisconsin, and Rhode Island.

### **What is the status of the six states that banned kratom at the request of the FDA?**

The FDA has vigorously engaged in a disinformation campaign against kratom for more than a decade. Six states did enact bans from 2021 to 2017, all in good faith, and all on the premise the FDA information was accurate: Alabama, Arkansas, Wisconsin, Indiana, Vermont, and Rhode Island. Now those states are starting to push back against the FDA disinformation and most are actively working to correct the mistakes made in response to the requests by the FDA.

- Vermont followed the FDA's recommendation to schedule kratom in 2016. Pursuant to a petition filed with the Vermont Department of Health to remove mitragynine and 7-hydroxymitragynine from the Regulated Drug Rule, the Department granted the petition submitted by the American Kratom Association (“AKA”) on March 1, 2023, and will commence rulemaking shortly to complete that process, stating as follows: “This email is to apprise you that the Department is granting your petition to remove mitragynine and 7-hydroxymitragynine from the Regulated Drug Rule.”
- Wisconsin is another state that banned kratom on the recommendation of the FDA, and the Wisconsin Controlled Substances Board (“CSB”) received a report from Dr. Chris Cunningham, Associate Professor of Pharmaceutical Sciences at Concordia University Wisconsin, with the following conclusion:

“Based on our review of the available literature, we conclude that regulation of *M. speciosa* in Wisconsin as a schedule-I substance is not justified at this time. We base this conclusion, in part, on the scientific evidence demonstrating that *M. speciosa* and its chemical constituents have lower potential for overdose and abuse relative to other agents that are not scheduled in this way. We believe that controlling *M. speciosa* and its chemical constituents under schedule-I harms public health and stifles much-needed research into its therapeutic and toxic properties.”

In response, members of the Wisconsin Legislature asked the CSB for an assessment of whether kratom's constituents meet the statutory requirements for scheduling under the 8-factor analysis. On March 10, 2023, the CSB approved a motion to affirm mitragynine and 7-hydroxymitragynine do not meet the required 8-factors for scheduling under Wisconsin law.

- The Interim Director of the Rhode Island Department of Health, Utpala Bandy, M.D., has acknowledged that kratom does not meet the criteria for scheduling set forth in Rhode Island statutes.
- In Indiana, the House of Representatives took the first step to remove the kratom ban and enact the Kratom Consumer Protection Act in a vote of 54-30 on February 21. The bill has now been transmitted to the Senate for action.

### **Is the FDA claim true that kratom is an opioid?**

No, kratom is not an opioid by plant genetics, by chemical structure, or by legal definition.

While some naturally occurring substances in kratom act on opioid receptors, kratom is not a prototypical opioid based on its chemical structure, botanical origins, or law – nationally or internationally. Like many natural products it has diverse effects and mechanisms of action that contribute to these effects and the reasons people use kratom.

Properly characterized as “partial agonists” some kratom constituents bind to opioid receptors and relieve pain whereas others do not. Unlike opioids which sedate and can impair mental functioning, kratom is used by many people in place of coffee for its alerting, mental focusing, and occupational performance enhancing effects.

Animal and human studies, as well as neuropharmacology mechanisms of action studies, show that kratom does not carry the substantial opioid-like risks of deadly respiratory depression or powerfully addictive euphoria. A misunderstanding of one of kratom's self-reported beneficial uses, recognized by researchers and NIDA, providing relief of opioid withdrawal, is sometimes interpreted as evidence that it must be an opioid. In fact, the nonopioid adrenergic blocking drugs developed for treating high blood pressure, clonidine and lofexidine, were prescribed for decades to treat opioid withdrawal. FDA approved lofexidine (Lucemyra) for treating opioid withdrawal in 2018. Mitragynine and other kratom constituents also produce adrenergic effects.

### **Is the FDA claim true that kratom is dangerously addictive?**

No, the FDA is completely wrong on this point. There is a significant difference between addiction and dependency, and there is a similar significant difference between a dangerous addiction and a socially acceptable benign addiction or dependency. Caffeine is the most widely used drug in the world and it has an addiction profile that is characterized by scientists, and the FDA, as having an acceptable addiction profile.

NIDA has conducted two specific animal studies on the addiction liability of kratom, with the following results:

- Abuse liability and therapeutic potential of the *Mitragyna speciosa* (kratom) alkaloids mitragynine and 7-hydroxymitragynine. "The present findings indicate that MG does not have abuse potential and reduces morphine intake, desired characteristics of candidate pharmacotherapies for opiate addiction and withdrawal, whereas 7-HMG should be considered a kratom constituent with high abuse potential that may also increase the intake of other opiates." (See <https://pubmed.ncbi.nlm.nih.gov/29949228/>)
- Abuse liability of mitragynine assessed with a self-administration procedure in rats. "These results suggest a limited abuse liability of mitragynine and potential for mitragynine treatment to specifically reduce opioid abuse. With the current prevalence of opioid abuse and misuse, it appears currently that mitragynine is deserving of more extensive exploration for its development or that of an analog as a medical treatment for opioid abuse." (See <https://pubmed.ncbi.nlm.nih.gov/30039246/>)

The available data suggest relatively low abuse potential as compared to morphine-like opioids, stimulants, and other drugs of abuse that demonstrate robust rewarding effects across all such abuse potential models. Similarly, MG's potential to produce physical dependence and withdrawal appears relatively low, but not absent, as compared to opioids in animal models. These findings are generally consistent with human reports that MG has a relatively low abuse and withdrawal potential as compared to recreationally used opioids but can reduce opioid self-administration and withdrawal.

### **Is the FDA claim true that kratom is a deadly drug that people are dying from?**

No, this FDA claim about deaths associated with kratom has been reviewed by experts and found to be untrue. It is well understood that kratom's respiratory effects are not like those of morphine-like opioids and peer-reviewed published studies since 2018 support the conclusion that kratom is not simply weaker than opioids with respect to respiratory depression, kratom does not cause respiratory suppression and associated overdose death.

Specifically, mitragynine and other alkaloids in kratom act as partial agonists at opioid receptors, meaning that their maximal effects reach a ceiling beyond which higher doses produce little additional effect. This was demonstrated in several animal species (including cats, dogs, mice, and rats) with mitragynine doses increased to levels far beyond what is or can be consumed by even high intake chronic kratom consumers.

The most recent study employed a sophisticated rodent model developed by FDA to compare a broad range of mitragynine doses to therapeutic and toxic oxycodone doses across blood gases and other parameters. Whereas oxycodone produced the signature dose-related plummeting blood oxygen levels and deaths, mitragynine produced no evidence of respiratory depression at any dose, and no life-threatening effects.

### **Why does the DEA list kratom as a "Drug of Concern"?**

The DEA has appropriately listed kratom as a "Drug of Concern" based on the conflicting reports made by the FDA, particularly with the deliberate adulteration and mislabeling of kratom products by some unscrupulous vendors in the kratom marketplace. Common adulterants include fentanyl, heroin, buprenorphine, and morphine. The DEA simply maintains surveillance of kratom to review reports of adverse events to potentially identify and interdict such adulteration with dangerous substances.

Importantly, kratom has never been listed by the DEA on their National Drug Threat Assessment (NDTA) report. This report assesses the threat posed to the U.S. by the trafficking and abuse of illicit drugs.

### **Why does the FDA have two import alerts on kratom?**

The FDA has used import alerts to create a de-facto ban on kratom since they cannot meet the requirements for scheduling under the Controlled Substances Act (CSA). While clearly an abuse of its regulatory authority, the premise of the import alerts are based entirely on the contrived and wholly inaccurate addiction and safety profile promoted by the FDA itself.

### **Can you overdose on kratom itself?**

The overall risk for kratom overdose appears at least 1,000 times lower for kratom as compared to opioids.

There were no deaths in which either the FDA or CDC confirmed as appropriately categorized as due to kratom consumption. Kratom consumers should not assume that kratom is without risk, but like many common consumer products, responsible use is a key safety factor. The CDC did not list kratom as a cause of any of the more than 108,000 drug overdose deaths in 2021, or in any other year of which we are aware.

In contrast, opioids were concluded by the CDC and NIDA to account for more than 80,000 overdose deaths in 2021. Overdose is possible with many readily available consumer substances, including caffeine, but kratom's most common side-effect, transient stomach upset and nausea, also limits intake and is discomforting but not seriously harmful. In February 2018, after announcing that kratom carried opioid-like death risk, the FDA noted that only one of 43 deaths occurring in kratom consumers did not involve other respiratory depressing substances. Further investigation found that the final cause was a motor vehicle fatality involving a kratom consumer.

In a review of the 44<sup>th</sup> death reported by the FDA to have been caused by kratom ingestion, when the autopsy report was obtained the actual cause of death was two gunshot wounds to the chest that occurred during a drug sting operation by law enforcement. The decedent had incidentally consumed a kratom tea on the morning he was shot.

NIDA, FDA, US DHHS, and WHO ECDD all have concluded that most kratom-associated deaths involved other substances.

### **What is the profile of the typical kratom consumer.**

According to surveys in the US, most consumers report are White adults, aged 35-55, with jobs and health care insurance, who report that their consumption is primarily for health and wellbeing. This includes consumption as an alternative to caffeinated products for alertness and increased focus, for the self-management of pain, and to improve mood.

Many consumers state that kratom worked better for them, had fewer side-effects than the FDA-approved medicines that had been taken, and/or that they preferred natural products. A smaller but especially important fraction of consumers are people who consider kratom as a "life-line" or a path away from opioids. They use kratom to manage opioid withdrawal and reduce or eliminate opioid use.

## What form do kratom products use in the marketplace?

It is well known that kratom has a bitter taste, which accounts for why pure, unadulterated kratom products are not attractive to minors. Kratom is sold in powder form, which is typically brewed into a tea by adding hot water – although some consumers consume the powder orally; in capsule or pill forms that bypass the bitter taste; and in liquids much like a five-hour energy drink. Kratom critics frequently point to kratom products being sold in convenience stores or gas stations as evidence of their harm. To the contrary, the most important protection for consumers is to make certain that every kratom product offered meets the manufacturing criteria for its content; is free from dangerous adulterants; is labeled properly; and is not sold to minors.

Some kratom products are “extracted” to (1) purify to remove any microbial contaminants; and (2) to standardize the alkaloid content of each serving size recommended for use of those products. Like any other consumer product similarly extracted, including coffee, plants and fruits, and essential oils, these extracts must use approved FDA food-grade solvents to complete the extraction process safely.

Many kratom critics claim all liquid kratom products are extracts. That is not true. Extracted kratom products are across all product forms, and the key to their safety is the use of safe extraction solvents and directions on appropriate serving sizes.

## What does recent science reveal about kratom?

Since 2018, there have been more than 100 new published research articles on kratom. While there are public references to that research, a recent presentation on new science on kratom was made at the UN Commission on Narcotic Drugs Conference in Vienna on March 16, 2023.

Here are links to video of presentations made by 4 of the world’s leading experts on kratom at that conference:

- Here is the link to the entire presentation (about 50 minutes long): <https://youtu.be/oztAWZAaxGo>
- Here are individual segments from each presenter – each is about 10 minutes long.
  - Dr. Marilyn Huestis, former NIDA official now with Thomas Jefferson University:  
<https://youtu.be/SbQtzs4uphQ>
  - Dr. Kirsten Smith, NIDA:  
<https://youtu.be/aLS-ZbV5klk>
  - Dr. Jack Henningfield, Pinney Associates and Johns Hopkins University:  
<https://youtu.be/oZj9TIFF8eI>

- Dr. Chris McCurdy, University of Florida:

<https://youtu.be/KBRXbRcydoE>

### **Summary:**

Kratom is safely used by consumers for a variety of purposes, chief of which is for its energy boost and increased focus effects, typically as a replacement for a cup of coffee. Research indicates kratom can act as a pain reliever for acute and chronic pain and potentially even treat opioid withdrawal. The National Institute on Drug Abuse (NIDA) has currently funded more than \$30 million in kratom research studies, including several grants totaling \$15 million at the University of Florida. The U.S. Congress issued Report Language in each of the last four annual budgets calling for further research to expand studies on kratom.

Pure kratom products, when used responsibly, are safe. Studies conducted by the NIDA confirm kratom has no significant addiction liability. Any deaths allegedly associated with kratom are due to adulterated kratom, polydrug use, or underlying health conditions. To protect American consumers, suitable public policy kratom solutions require appropriate regulation.

For additional information go to [www.kratomanswers.org](http://www.kratomanswers.org).







September 21, 2022

Michigan State Senator Ruth Johnson

P.O. Box 30036  
Lansing, MI 48909-7536

**RE: HB 5477 – the Kratom Consumer Protection and Regulatory Act**

Dear Senator Johnson,

I have worked in the public health arena for over 25 years. The Community Health Center that I have the privilege of leading provides medication assisted treatment to treat opioid and alcohol addiction. When doing our urine drug screens for our patients, they frequently test positive for kratom. Patients believe kratom is safe because it is sold over the counter. kratom has been marketed to the public as a mood enhancer, pain reliever, and antidote for opioid withdrawal.

Given that kratom is not regulated, and the amount of active ingredient in the plant can vary greatly. Claims about the benefits of kratom cannot be evaluated because reliable evidence is lacking. What we do know is that poison control centers in the United States received about 1,800 reports involving use of kratom from 2011 through 2017, including reports of death. About half of these exposures resulted in serious negative outcomes such as seizures and high blood pressure. Five of the seven infants who were reported to have been exposed to kratom went through withdrawal. Kratom has been classified as possibly unsafe when taken orally.

Please consider supporting HB 5477 to protect the public from this potentially dangerous plant derivative.

Respectfully,

Karen Wood  
Chief Executive Officer

Administrative Offices  
6800 East Ten Mile Road  
Center Line, MI 48015  
PH 586.619.9986  
FX 586.806.5085

6900 East Ten Mile Road  
Center Line, MI

- Medical -

PH 586.756.7777  
FX 586.756.7788

- Dental -

PH 586.467-0980  
FX 586.756.7788

- Primary Care
- Dental
- Behavioral Health
- Women's Health Services

18 Market Street, Suite C  
Mt. Clemens, MI 48043  
PH 586.783.2222  
FX 586.783.6280

- Primary Care
- Behavioral Health
- Medication Assisted Treatment
- Women's Health Services

43740 North Groesbeck Highway  
Clinton Township, MI 48036  
PH 586.493.0961  
FX 586.493.1001

- Primary Care
- Behavioral Health

- /MyCareHealthCenter
- @MyCareHealthCenter
- @MyCare\_Health

www.mycarehealthcenter.org





**MICHIGAN NURSES ASSOCIATION**

2310 Jolly Oak Road  
Okemos, MI 48864  
Phone: 517-349-5640  
Fax: 517-349-5818  
Web: [www.minurses.org](http://www.minurses.org)



Sept. 26, 2022

Dear members of the Senate Regulatory Reform Committee,

The Michigan Nurses Association respectfully urges your support of HB 5477, the Kratom Consumer Protection and Regulatory Act, sponsored by Rep. Lori Stone. As you heard from Rep. Stone in committee, this bipartisan bill addresses the need to regulate kratom (*Mitragyna speciosa*).

While further research is certainly warranted, it is appropriate at this time for state government to develop standards to protect the public. We agree that the best approach is information, education and regulation to mitigate potential harm.

Requiring a license for the distribution, sale or manufacture of kratom is integral to protecting the health and safety of consumers. Consumers deserve to know what they are buying and to make informed decisions, in collaboration with their healthcare provider, which is why the required product label and disclosure of the alkaloid content and the amount of mitragynine and 7-hydroxymitragynine are so important. It is also appropriate to require that consumers be 21 and older.

We believe that this bill is vital to protecting the health and safety of the public and we urge you to support it.

As always, please feel free to contact me with any questions or concerns.

Sincerely,

Dawn Kettinger  
Government Affairs Director  
Michigan Nurses Association  
(517) 721-9688  
[dawn.kettinger@minurses.org](mailto:dawn.kettinger@minurses.org)

## Memo

To: Chairman Nesbitt and Members of the Senate Regulatory Reform Committee  
From: Sean Sorenson-Abbott, Manager, Government Relations  
Date: June 2022  
Re: HB 5477 – The Kratom Consumer Protection Act  
Position: Support

---

The Michigan Health and Hospital Association (MHA) is supportive of HB 5477, also known as the Kratom Consumer Protection Act. Introduced by Rep. Lori Stone (D-Warren), HB 5477 would regulate the sale and production of Kratom products in Michigan and create some general safeguards to protect consumers.

Kratom is a tropical tree native to Southeast Asia, with leaves that contain compounds which can have psychotropic effects similar to opioids and stimulants. Kratom's ingredients bind to the same receptors in the brain that opioid painkillers do without the same tendency to depress breathing. The plant can be eaten raw, but more often is crushed and brewed as tea or turned into capsules, tablets, and liquids. According to consumers, kratom is used to treat pain, mood disorders (such as anxiety and depression), opioid addiction and to ease opioid withdrawal.

The Food and Drug Administration (FDA) has been outspoken about their concerns involving kratom because it appears to have properties that expose users to the risks of addiction, abuse, and dependence. They are especially concerned about the use of kratom to treat opioid withdrawal symptoms, as there is no reliable evidence to support the use of kratom as a treatment for opioid use disorder and significant safety issues exist. Also, scientists from the FDA found dangerously high levels of heavy metals, including lead, in kratom products. A long-term kratom user could potentially develop heavy metal poisoning leading to nervous system or kidney damage, anemia, high blood pressure, and is at increased risk of certain cancers. There are currently zero FDA-approved uses for Kratom.

HB 5477 would create a new license applicable to all Kratom manufacturers, distributors, or dealers. The bill would ban adulterated Kratom products, require warning labels addressing the potential health impacts, and require lab testing for Kratom products to ensure consumers know what substances are present.

The MHA maintains that kratom should be defined as a federal schedule 1 narcotic and has previously opposed attempts to regulate kratom as a schedule 2. The Kratom Consumer Protection Act will provide state regulation and oversight that will help prevent potential misuse in the short term while the MHA continues to advocate for a federal ban.

**Brian Peters**, Chief Executive Officer

23 September 2022

Elizabeth Anne Lucas MSN, RN, APRN, PMHNP-BC  
1416 North Renaud Road  
Grosse Pointe Woods, MI 48236  
313-587-7529  
Lucase49@macomb.edu

I support HB 5477, and here is why:

I am a Board-Certified Nurse Practitioner who specializes in Psychiatric/Mental Health. I am certified in trauma counseling. I also am a Professor of Nursing at Macomb Community College. I teach lecture and directly with students on the specialty mental health units of two Macomb County hospitals.

I have seen the devastation that addiction has brought to our communities. My students have lost parents, spouses, and friends to opiate addiction. I personally have a cousin that is addicted to opioids, and he was saved by the Narcan that CARE trained me to use and provided for me.

Many of my patients who have overdosed 6 or more times, some willingly consuming Fentanyl for that high. Most substances that my patients are now consuming are contaminated with Fentanyl, and the patients are exposed to this whether they are aware of it or not. This is a disturbing trend that has severe consequences for the patients.

Now I am seeing a very different thing: Kratom.

I became aware of this herbal extract four years ago when a patient on the unit I was teaching was withdrawing but had a negative drug screen. The withdrawal process looked like opiate withdrawal, and their liver enzymes were alarmingly elevated. It was this patient's first admission, but the patient didn't recover and became one of the patients caught in a very expensive revolving door of illness-admission to hospital-discharge.

During that time, a student in their early twenties disclosed to me that they were using Kratom for pain control due to an injury. I had another whose neighbor gave them a bottle of herbal "vitamins" that would help with the pain from a back injury that resulted from a violent patient. Those "vitamins" were Kratom.

Another older student told me their neighbour had seen the student groaning while working in the yard, and he gave the student "some herbal pills" that would work on their arthritis, and they would not feel pain. The student sent a picture of the package, and yes, it was Kratom. The student stated they were grateful they had not taken any of the pills.

I started asking patients on my floor about Kratom. On 22 September 2022, 10 people told me directly that they use Kratom—this was an increase since February 2022. The reasons were: stop withdrawal from heroin, to enhance the high they get from heroin & fentanyl, and for pain control. The patients said they are buying it from smoke shops, gas stations, and party stores. No ID is checked, and the patients said that they have seen very young customers with backpacks and book bags buying Kratom. It can be ordered online.